Evolent Health, Inc (EVH) Holdings Raised by Swiss National Bank
Swiss National Bank raised its holdings in Evolent Health, Inc (NYSE:EVH) by 43.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,400 shares of the technology company’s stock after acquiring an additional 26,400 shares during the quarter. Swiss National Bank owned 0.14% of Evolent Health worth $2,216,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in EVH. BNP Paribas Arbitrage SA boosted its position in shares of Evolent Health by 815.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock worth $120,000 after purchasing an additional 4,232 shares in the last quarter. US Bancorp DE increased its holdings in shares of Evolent Health by 0.3% in the 1st quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after purchasing an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in shares of Evolent Health in the 1st quarter valued at about $126,000. Bank of Montreal Can increased its holdings in shares of Evolent Health by 4,249.7% in the 1st quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after purchasing an additional 6,077 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Evolent Health by 286.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock valued at $150,000 after purchasing an additional 5,000 shares in the last quarter. 82.51% of the stock is owned by institutional investors.
Shares of Evolent Health, Inc (NYSE EVH) opened at 18.65 on Wednesday. Evolent Health, Inc has a 12 month low of $14.50 and a 12 month high of $25.66. The stock’s market capitalization is $1.23 billion. The stock has a 50 day moving average price of $17.27 and a 200 day moving average price of $17.27.
Evolent Health (NYSE:EVH) last released its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The company’s revenue was up 89.9% compared to the same quarter last year. During the same period last year, the company posted ($0.20) EPS. On average, analysts anticipate that Evolent Health, Inc will post ($0.41) EPS for the current fiscal year.
In related news, CEO Frank J. Williams sold 16,300 shares of Evolent Health stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $24.76, for a total value of $403,588.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Thomas Peterson III sold 40,540 shares of Evolent Health stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $26.00, for a total value of $1,054,040.00. The disclosure for this sale can be found here. Insiders have sold 80,807 shares of company stock worth $2,034,642 over the last ninety days. 8.79% of the stock is owned by insiders.
EVH has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a report on Wednesday, September 6th. KeyCorp assumed coverage on shares of Evolent Health in a research report on Tuesday, September 19th. They set an “overweight” rating and a $23.00 price target for the company. Robert W. Baird reissued an “outperform” rating and set a $25.00 price target (down previously from $35.00) on shares of Evolent Health in a research note on Tuesday, September 26th. They noted that the move was a valuation call. Cowen and Company reissued an “outperform” rating and set a $35.00 price target on shares of Evolent Health in a research note on Wednesday, June 28th. Finally, BidaskClub cut Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $28.50.
Evolent Health Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.